Navigation Links
Precision Therapeutics President and CEO Sean McDonald Recognized as Pittsburgh Technology Council Tech 50 CEO of the Year
Date:10/15/2010

PITTSBURGH, Oct. 15 /PRNewswire/ -- Precision Therapeutics announced today that its President and Chief Executive Officer Sean McDonald was recognized as CEO of the Year by the Pittsburgh Technology Council.

(Photo: http://photos.prnewswire.com/prnh/20101015/NE83126 )

(Photo: http://www.newscom.com/cgi-bin/prnh/20101015/NE83126 )

The Tech 50 award recognizes the accomplishments of 50 of southwestern Pennsylvania's most successful entrepreneurs whose innovation and creativity have been used to strategically enhance the ideals and growth of their organization as well as the community and greater region. McDonald was selected by an independent panel of technology experts and the category awards were presented on October 14, 2010, at the Hilton Downtown Pittsburgh.

Sean joined Precision in 2001 and has since dedicated his career to developing innovative technologies with the goal of helping physicians to select customized treatment to meet the individual needs of each cancer patient. He most recently led Precision to earn a first place ranking as an industry leader in the health care division in the Pittsburgh region.  Because of Sean's passion, leadership and vision, Precision Therapeutics remains at the forefront of personalized diagnostics and research for individualized cancer therapy, with nearly 32,000 patient specimens sent for ChemoFx® testing and 18 active clinical trials.

About Precision Therapeutics

Precision Therapeutics, a life-science company based in Pittsburgh, Pennsylvania, is committed to improving outcomes of cancer patients. As leaders in the science of individualizing cancer therapy through the use of a proprietary and unique live-tissue platform, Precision develops novel markers to help guide treatment decisions based on the biological processes of each individual's cancer.

Precision's state of the art bioinformatics combined with the analysis of the live molecular, proteomic and genomic activity of each patient's cancer offer an innovative foundation for further development and commercialization of novel predictive markers for cancer therapy.  Precision's first commercial test, ChemoFx®, is a proprietary drug response marker which measures an individual's malignant tumor response to a range of standard therapeutic alternatives under consideration by a physician.

For more information, please visit www.chemofx.com.


'/>"/>
SOURCE Precision Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Applied Precision Installs New DeltaVision
2. OMX® Super-Resolution Imaging System in the Light Microscopy Imaging Center at Indiana University
3. Pinpoint precision: Delivering a biochemical payload to 1 cell
4. Precision Therapeutics Growing Rapidly as it Augments Research and Development Efforts
5. Stretching single molecules allows precision studies of interacting electrons
6. Precision Antibody Wins Contract to Develop Gold Standard Antibodies as Part of National Cancer Institutes Clinical Proteomics Technologies for Cancer (CPTC) Initiative
7. Precision Therapeutics Named to Inc. Magazines List of Fastest Growing Companies
8. New statistical technique improves precision of nanotechnology data
9. Precision Stability Storage Announces Upcoming Expansion
10. NISTs LIDAR may offer peerless precision in remote measurements
11. Frost & Sullivan Awards Precision Biosciences for Technology Innovation and Molecular Design Process in the Genomics Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... /PRNewswire/ - Portage Biotech Inc. ("Portage" or "the Company") ... announce that Biohaven has issued today the following press ... (PRWEB) Dec 9, 2016 - Biohaven Pharmaceutical Holding ... the U.S. Food and Drug Administration ("FDA") has granted ... candidate BHV-0223, an orally dissolving tablet being developed for ...
(Date:12/8/2016)... -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS ... today announced financial results for the fiscal first ... on our commitment to address an unmet medical ... pleased with the early clinical response data presented ... focused on advancing our lead program – ImmunoPulse® ...
(Date:12/8/2016)... , Dec. 8, 2016 Eurofins announces the appointment ... and President of Eurofins Scientific Inc. (ESI). Mr. ... his proven professional and entrepreneurial experience in leading international business teams. ... US food testing market to uphold Eurofins, status as the global ... ...
(Date:12/8/2016)... BARCELONA, Spain , Dec. 8, 2016  Anaconda ... on the development of the next generation neuro-thrombectomy system ... the appointment of Tudor G. Jovin, MD to join ... to serve as a strategic network of scientific and ... progresses the development of the ANCD BRAIN ® ...
Breaking Biology Technology:
(Date:11/22/2016)... 2016 According to the new market research report ... Vein, Signature, Voice), Multi-Factor), Component (Hardware and Software), Function (Contact and Non-contact), ... market is expected to grow from USD 10.74 Billion in 2015 to ... 2016 and 2022. Continue Reading ... ...
(Date:11/21/2016)...   Neurotechnology , a provider of high-precision ... that the MegaMatcher On Card fingerprint matching algorithm ... NIST Minutiae Interoperability Exchange (MINEX) III ... of the evaluation protocol. The ... fingerprint templates used to establish compliance of template ...
(Date:11/17/2016)... -- Global Market Watch: Primarily supported by ownership ... and Academics) market is to witness a value of US$37.1 ... highest Compounded Annual Growth Rate (CAGR) of 10.75% is foreseen ... period 2014-2020. North America is not ... Europe at 9.56% respectively. Report Focus: ...
Breaking Biology News(10 mins):